Generic Name and Formulations:
Apraclonidine (as HCl) 0.5%; oph. soln; contains benzalkonium chloride.
Alcon Laboratories, Inc.
Indications for IOPIDINE:
Short-term adjunctive therapy to reduce elevated IOP.
Remove contact lenses; may reinsert 15min after instillation. 1–2 drops 3 times daily. Allow at least 5min between instillation of other oph drugs.
Clonidine allergy. Concomitant MAOIs.
Monitor visual fields. Severe uncontrolled cardiovascular disease, hypertension, coronary insufficiency. Recent myocardial infarction. Cerebrovascular disease. Raynaud's syndrome. Thromboangiitis obliterans. Discontinue if ocular allergic-like reactions occur. Renal or hepatic impairment: closely monitor cardiovascular parameters. Depression. Masks hypoglycemia. Pregnancy. Nursing mothers.
Hypertensive crisis with MAOIs. May potentiate CNS depressants, alcohol. May be antagonized by tricyclic antidepressants. Additive hypotensive effects with neuroleptics; hypotensive and pulse effects with β-blockers, antihypertensives, cardiac glycosides, others (eg, clonidine).
Hyperemia, pruritus, dry mouth, itching, discomfort, tearing, dizziness, solmnolence, lid edema, blurred vision, foreign body sensation, dry eye, conjunctivitis, discharge, blanching, headache, asthenia, dry nose, taste perversion; tachyphylaxis may develop after 1 month.
Renal and Urology News Articles
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)